Source: Eur Respir J, 53 (2) 1802250; 10.1183/13993003.02250-2018
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Parameswaran Nair, Paul M. O'Byrne. The interleukin-13 paradox in asthma: effective biology, ineffective biologicals. Eur Respir J, 53 (2) 1802250; 10.1183/13993003.02250-2018

Member's Comments

No comment yet.

Related content which might interest you: Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment Year: 2009 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies Year: 2009 New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5 Source: Eur Respir J 2001; 17: 499-506 Year: 2001 A new combination therapeutic approach challenging the current dogma of using inhaled corticosteroids as maintenance only to control asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006 Biological and therapeutic implications of the united airways disease concept Source: Annual Congress 2005 - PG18 - Inter-relationships between upper and lower airway diseases Year: 2005 New phenotyping of corticosteroid-resistant asthma based on molecular mechanisms Source: Annual Congress 2005 - Genetic polymorphisms and molecular mechanisms in asthma pathophysiology Year: 2005 The basic science behind asthma biologics Source: International Congress 2018 – New biologics for asthma: which patients, which agents, which results, at what cost? Year: 2018 New and future developments of therapy for asthma in children Source: Eur Respir Mon 2012; 56: 224-234 Year: 2012 Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives Source: Eur Respir Rev 2015; 24: 594-601 Year: 2015 Emerging biologic approaches for the treatment of difficult to control asthma Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma Year: 2017 Introduction: pharmacogenetic approaches in the treatment of asthma Source: Annual Congress 2005 - Genetic polymorphisms and molecular mechanisms in asthma pathophysiology Year: 2005 Biologic therapies in paediatric severe asthma Source: ERS webinar 2020: Biologic therapies in paediatric severe asthma Year: 2020 Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Do we need new therapies for noneosinophilic asthma? Source: Annual Congress 2004 - Noneosinophilic asthma Year: 2004 What is the role of oral corticosteroids in the era of biologics in asthma? Source: International Congress 2019 – State of the art session: Airway disease Year: 2019 Airway inflammation in asthma: current and future targets and therapies Source: Breathe 2010; 6: 245-252 Year: 2010 An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Are we really transforming asthma and COPD management with biologics? Source: International Congress 2018 – State of the art session: Airways disease Year: 2018